Preventing progression to reduce costs: A cost-effectiveness analysis of enfortumab vedotin+pembrolizumab in MIBC

European Journal of Cancer · Elsevier

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →

Similar articles